CERUS CORP Quarterly Report Released - Here’s What You Should Know

Investor Summary – Cerus Corporation Q2 2025

Key Financial Metrics

• Revenue: Total revenue for the quarter ended June 30, 2025, was $60.1 million, up 19% from $50.5 million in Q2 2024. Six-month revenue was $109.0 million, up 16% from $93.9 million year-over-year.
• Product Revenue: $52.4 million in Q2 2025 (+16% YoY); $95.7 million for the first six months (+15% YoY).
  • By Region Q2 2025: North America $35.3 million, EMEA $16.6 million, Other $0.5 million.
• Government Contract Revenue: $7.7 million in Q2 2025 (+41% YoY); $13.3 million year-to-date (+27% YoY).
• Gross Profit: Product revenue gross margin was 55% for Q2 2025 (unchanged YoY), year-to-date gross margin was 57% (vs. 55% YTD 2024).
• Net Loss: Q2 2025 net loss attributable to Cerus was $5.7 million (EPS: $(0.03)); six-month net loss was $13.4 million (EPS: $(0.07)). This compares to $5.8 million net loss (EPS: $(0.03)) and $15.5 million net loss (EPS: $(0.08)) YoY.
• R&D Expenses: $18.9 million in Q2 (+26% YoY); $35.5 million YTD (+21% YoY), driven by inflationary pressures and ongoing development programs.
• SG&A Expenses: $21.2 million in Q2 (+12% YoY); $41.5 million YTD (+7% YoY).
• Operating Cash Flow: For the first six months, net cash used was $3.3 million (vs. $2.4 million provided in 1H 2024).
• Cash, Equivalents & Short-Term Investments: $79.2 million as of June 30, 2025 ($81.5 million as of Dec. 31, 2024).
• Debt: Total debt stood at $84.9 million (current $28.1 million, non-current $56.8 million), with scheduled principal payments beginning in 2026.
• Working Capital: $84.6 million at June 30, 2025 ($88.9 million at Dec. 31, 2024).
• Shares Outstanding: 191,698,794 as of July 17, 2025.

Key Customer Concentration

• American Red Cross: 33% of Q2 2025 product revenue.
• Établissement Français du Sang (EFS): 10% of Q2 2025 product revenue.
• OneBlood: 11% of Q2 2025 product revenue.

Risks

• High Customer Concentration: Significant dependence on a few key customers (e.g., American Red Cross at 33%, EFS at 10%) exposes Cerus to revenue volatility if these relationships change (page 335).
• Manufacturing & Supply Chain Risks: Cerus relies on third-party manufacturers and suppliers, with risks including supply disruptions, component shortages (notably for illuminators), and single-source dependencies (pages 61-64).
• Regulatory Risks: Changes or failures in regulatory approvals (e.g., required new PMAs for updated products, uncertainty of EU MDR recertification, or FDA post-market requirements) could affect commercialization (pages 47-50, 49).
• Government Contract Risks: Significant funding for R&D (especially RBC system) comes from BARDA, FDA, and DoD contracts, which may be canceled, reduced, or not fully exercised based on milestone achievement or U.S. government priorities (pages 56-58).
• Product Adoption: Success depends on achieving broad market adoption of INTERCEPT systems for platelets, plasma, and cryoprecipitation. Risks include processing inefficiencies and costs perceived by customers (page 37).
• Market Competition: Competing pathogen reduction and blood safety technologies—as well as shifting hospital/center preferences—can impact Cerus’ market share (pages 42-43).
• Liquidity: While Cerus holds $79.2 million in liquid assets, it continues to generate net losses, and future capital requirements may necessitate equity or debt financing (page 31).
• International Risks: Currency fluctuations, trade barriers (tariffs), and economic or political instability may impact financial results and supply chain operations (pages 67-68).
• Legal & Compliance: Exposure to federal and international healthcare, anti-kickback, and data privacy laws increases compliance costs and risk of regulatory penalties (pages 51-55).

Management Discussion

• Revenue Growth: Revenue increase was driven by higher demand for INTERCEPT Blood System products in North America and EMEA, with corresponding government contract strengths from BARDA, FDA, and DoD for development work (pages 27, 343-347).
• Margin Management: Gross margin on product revenue held steady at 55% despite higher cost of sales, reflecting efficiencies and favorable product mix (page 28, 355).
• Cost Pressures: Increases in R&D and SG&A reflect inflationary labor and supply costs as well as investment in product pipeline development, particularly for the red blood cell system and compliance with evolving global regulations (page 362, 369).
• Cash Utilization: While net cash usage was modest relative to cash reserves, management highlights the need for continued discipline in working capital, inventory management, and expense controls—especially with scheduled debt principal repayments beginning in 2026 and potential need for further capital raising (pages 405, 31-32).
• Market Risks: Management identifies concentrated customer base, supply chain resilience, regulatory compliance, and macroeconomic trends (inflation, geopolitical conflict, tariffs) as continued risks to monitor.
• Product & Pipeline: Progress continues on clinical development for the red blood cell system—full enrollment in RedeS trial expected by end of 2025—and expanding indications for the INTERCEPT platform (page 46).
• Government Funding: Management is optimistic about anticipated future government contract funding but flags “no assurance” that options will be exercised or milestones achieved for full reimbursement (pages 56-57).
• No Legal Proceedings: No material litigation or regulatory actions as of the report date (page 34).

Conclusion

Cerus reported double-digit revenue growth and stable margins but continues to operate at a net loss, with a concentrated revenue stream reliant on a few key customers and government contracts. Investor focus should remain on cash burn, cost management, execution of product pipeline, customer diversification, and navigating regulatory hurdles. Risks related to supply chain, reimbursement, government funding, and evolving market/regulatory landscapes are material and should be monitored closely.

Visit Publicview AI to search and analyze millions of SEC filings using AI.